Combined Therapy with Desferal and Deferioprone in Improvement of Heart Function in Thalassemic Patients

Noormohammad Noori; Peyman Eshghi; Fatemeh shahramian

Zahedan Journal of Research in Medical Sciences

The Official Journal of Zahedan University of Medical Sciences

Current Issue All Issues In Press Articles Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Combined Therapy with Desferal and Deferioprone in Improvement of Heart Function in Thalassemic Patients

Author(s):

Noormohammad Noori¹,

Peyman Eshghi²,

Fatemeh shahramian^3,*

1Prof, Research Center for Children and Adolescent's Health and Dept of Pediatric Cardiology, Zahedan University of Medical Sciences, Zahedan, Iran.

2Associate Prof, Dept of Pediatric Hematology and Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3Resident of Pediatrics, Research Center for Children and Adolescent's Health, Zahedan University of Medical Sciences, Zahedan, Iran.

Zahedan Journal of Research in Medical Sciences:Vol. 11, issue 4; e94362

Published online:Dec 27, 2009

Article type:Research Article

Received:May 27, 2009

Accepted:Nov 15, 2009

How to Cite:Noormohammad NooriPeyman EshghiFatemeh shahramianCombined Therapy with Desferal and Deferioprone in Improvement of Heart Function in Thalassemic Patients.Zahedan J Res Med Sci.11(4):e94362.

Abstract

Background: Cardiac complications due to iron overload are the most common causes of death in patients with major thalassemia. This study assessed the efficacy of iron chelating by desferal-L1 in improvement of cardiac function in patients with major thalassemia.

Methods and Materials : Patients older then 8 years old with major thalassemia that were admitted to hematology ward of Ali-e-Asghar hospital of Zahedan in 2005-2006 and had lower than normal diastolic indices in annual echocardiography were considered as study population. During primary tests, indices of diastolic function of left and right hearts were calculated, using echocardiography with 2D, M-mode and Doppler then the patients were placed on a combination of desferal (30-40mg/kg/day two nights per week) and L1 (deferiprone) (75mg/kg/day, three times a day). At the end of the study, cardiac indices were calculated again. Data were using SPSS software and paired t-test and p <0.05 was considered as significant level.

Results : Of 38 patients, who were treated with a combination of desferal-L1, 19 were female with the mean age of 16.9 ± 3.1 and 18 were male with the mean age of 17.3 ± 2.6 years. Diastolic indices of right ventricle had no significant difference before and after treatment except PET/ET which decreased significantly after treatment ( p <0.05). Of diastolic indices of left ventricule peak-E-velocity and IVRT and E/A ratio decreased significantly after treatment ( p <0.05). t he difference of peak-A-velocity before and after treatment was not significant ( p >0.05). Systolic indices of left ventricule increased significantly after treatment ( p <0.05).

Conclusion : In this study, after one year of treatment with a combination of desferal-L1 in patients with major thalassemia, echocardiography showed improvement in left heart systolic and diastolic function. This combination therapy prevented progression of right ventricular diastolic function abnormality

Keywords

Major beta thalassemia

Echocardiography

Desferal

Deferiprone

Fulltext

The full text of this article is available on the PDF file.

References

1.
The References of this article are available on the PDF file.

comments